The DOI matches its Crossref record.
Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2.
Abstract
Transforming growth factor (TGF)-beta 1 is a polypeptide that is assumed to play a fundamental role in the growth of both normal and neoplastic cells. TGF-beta 2 is a closely related polypeptide, originally described as glioblastoma cell-derived T cell suppressor factor (G-TsF) due to its immunosuppressive activity. Expression of the genes for TGF-beta 1 and G-TsF/TGF-beta 2 was examined in tumor cells and was found to be different in several cell lines and tissues that were tested. Whereas two glioblastoma cell lines expressed both TGF-beta 1 and G-TsF/TGF-beta 2 mRNA, one melanoma and neuroblastoma cell lines showed only TGF-beta 1 mRNA which in the case of the neuroblastoma required cycloheximide treatment for its detection. The coordinate expression of the genes for TGF-beta 1 and G-TsF/TGF-beta 2 in glioblastoma was not paralleled by secretion of both polypeptides as only G-TsF/TGF-beta 2 but not TGF-beta 1 was identified in supernatants of glioblastoma cells. These data provide evidence for a post-transcriptional level of regulation for production of the two forms of TGF-beta. As mRNA for G-TsF/TGF-beta 2 was also identified in fresh surgically removed human glioblastoma tissue, G-TsF/TGF-beta 2 may also be secreted within the tumor in vivo. Unlike glioblastoma, human fetal brain tissues or adult brain specimens studied did not express detectable levels of TGF-beta mRNA. Impaired cell-mediated immunity is an established finding in patients with glioblastoma. Secretion of G-TsF/TGF-beta 2 by tumor cells in vivo may contribute to decreased immune surveillance for tumor development, as well as neovascularization of the tumor tissue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
Current state of immunotherapy for glioblastoma
Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,365
Streit, W. J., Walter, S. A., & Pennell, N. A. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00069-0 · Cited by 1,096
Role of Transforming Growth Factor Beta in Human Cancer
Elliott, R. L., & Blobe, G. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.047 · Cited by 709
Immune microenvironment of gliomas
Gieryng, A., Pszczolkowska, D., Walentynowicz, K. A., Rajan, W. D., & Kaminska, B. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.19 · Cited by 538
Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer
Pardali, K., & Moustakas, A. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.06.004 · Cited by 526
Schultz-Cherry, S. (1993) · The Journal of Cell Biology · doi:10.1083/jcb.122.4.923 · Cited by 468
Bogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N. K., Mahapatra, A. K., Suri, A., Balasubramaniam, A., Nair, S., Oliushine, V., Parfenov, V., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq142 · Cited by 433
Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?
Saas, P., Walker, P. R., Hahne, M., Quiquerez, A. L., Schnuriger, V, Perrin, G., French, L., Van Meir, E. G., de Tribolet, N., Tschopp, J., et al. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119273 · Cited by 398
Self-citationNemunaitis, J., Dillman, R. O., Schwarzenberger, P. O., Senzer, N., Cunningham, C., Cutler, J., Tong, A., Kumar, P., Pappen, B., Hamilton, C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.5335 · Cited by 367
The host—tumor immune conflict: from immunosuppression to resistance and destruction
Chouaib, S., Asselin-Paturel, C., Mami-Chouaib, F., Caignard, A., & Blay, J. Y. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01115-8 · Cited by 350
Weller, M., Frei, K., Groscurth, P., Krammer, P. H., Yonekawa, Y., & Fontana, A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117462 · Cited by 345
Self-citationThe molecular profile of microglia under the influence of glioma
Li, W., & Graeber, M. B. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos116 · Cited by 340
Fakhrai, H., Dorigo, O., Shawler, D. L., Lin, H., Mercola, D., Black, K. L., Royston, I., & Sobol, R. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2909 · Cited by 334
Immune defects observed in patients with primary malignant brain tumors
Dix, A. R., Brooks, W. H., Roszman, T. L., & Morford, L. A. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00203-9 · Cited by 323
Role of Exosomes/Microvesicles in the Nervous System and Use in Emerging Therapies
Lai, C. P.-K., & Breakefield, X. O. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00228 · Cited by 315
Friese, M. A., Wischhusen, J., Wick, W., Weiler, M., Eisele, G., Steinle, A., & Weller, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1627 · Cited by 305
When Immune Cells Turn Bad—Tumor-Associated Microglia/Macrophages in Glioma
Roesch, S., Rapp, C., Dettling, S., & Herold-Mende, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020436 · Cited by 293
Wahl, S. M., Allen, J. B., McCartney-Francis, N., Morganti-Kossmann, M. C., Kossmann, T., Ellingsworth, L., Mai, U. E., Mergenhagen, S. E., & Orenstein, J. M. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.4.981 · Cited by 291
Tumor-derived exosomes in the regulation of macrophage polarization
Baig, M. S., Roy, A., Rajpoot, S., Liu, D., Savai, R., Banerjee, S., Kawada, M., Faisal, S. M., Saluja, R., Saqib, U., et al. (2020) · Inflammation Research · doi:10.1007/s00011-020-01318-0 · Cited by 267
Shintani, Y., Maeda, M., Chaika, N., Johnson, K. R., & Wheelock, M. J. (2008) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2007-0071oc · Cited by 259
Immunocompetent murine models for the study of glioblastoma immunotherapy
Oh, T., Fakurnejad, S., Sayegh, E. T., Clark, A. J., Ivan, M. E., Sun, M. Z., Safaee, M., Bloch, O., James, C. D., & Parsa, A. T. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-107 · Cited by 255
Zhu, L. X., Sharma, S., Stolina, M., Gardner, B., Roth, M. D., Tashkin, D. P., & Dubinett, S. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.1.373 · Cited by 252
Targeted tumor therapy with the TGF-β2 antisense compound AP 12009
SCHLINGENSIEPEN, K., SCHLINGENSIEPEN, R., STEINBRECHER, A., HAU, P., BOGDAHN, U., FISCHERBLASS, B., & JACHIMCZAK, P. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.002 · Cited by 195
Nemunaitis, J., Nemunaitis, M., Senzer, N., Snitz, P., Bedell, C., Kumar, P., Pappen, B., Maples, P. B., Shawler, D., & Fakhrai, H. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.15 · Cited by 147
Jachimczak, P., Bogdahn, U., Schneider, J., Behl, C., Meixensberger, J., Apfel, R., Dörries, R., Schlingensiepen, K.-H., & Brysch, W. (1993) · Journal of Neurosurgery · doi:10.3171/jns.1993.78.6.0944 · Cited by 146
Glioblastomas Induce T-Lymphocyte Death by Two Distinct Pathways Involving Gangliosides and CD70
Chahlavi, A., Rayman, P., Richmond, A. L., Biswas, K., Zhang, R., Vogelbaum, M., Tannenbaum, C., Barnett, G., & Finke, J. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4395 · Cited by 141
Gray, C. P., Franco, A. V., Arosio, P., & Hersey, P. (2001) · International Journal of Cancer · doi:10.1002/ijc.1269 · Cited by 70
Metadata
- Authors
- Bodmer, S., Strommer, K., Frei, K., Siepl, C., de Tribolet, N., Heid, I., & Fontana, A.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1989-11
- Volume
- 143
- Issue
- 10
- Pages
- 3222-3229
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1528827595
- Cited by
- 386
- References
- 0
- FWCI
- 5.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.